EIF2B5

Across TCGA pan-cancer cohorts, EIF2B5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EIF2B5 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF2B5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF2B5 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where EIF2B5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.675	0.920	<.001	29	view →
COAD	DFS	Quartile	II,III,IV	1.000	0.876	.039	24	view →
CCRCC	OS	Tertile	All	0.886	1.000	.011	7	view →
LUAD	DFS	Quartile	All	0.951	0.855	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EIF2B5–PDAC (DFS)

Open the PDAC breakdown →